Onco-BCG 40 mg

Onco-BCG 40 mg is a prescription immunotherapy medicine containing BCG, shown as a Cipla product. It is used by intravesical instillation, meaning it is placed directly into the urinary bladder through a catheter by trained healthcare staff. Tiny vial, massive “please don’t confuse this with a vaccine” warning.

BCG intravesical therapy is used for certain types of non-muscle invasive bladder cancer, including carcinoma in situ and prevention of recurrence after bladder tumor removal, depending on the urologist’s treatment plan. It is not intended for tuberculosis vaccination.

Composition:

BCG for Immunotherapy I.P. – 40 mg

Key Information:

Brand Name: Onco-BCG
Strength: 40 mg
Active Ingredient: Bacillus Calmette-Guérin / BCG
Dosage Form: Freeze-dried injection / lyophilized vial
Medicine Type: Intravesical immunotherapy / biological response modifier
Manufacturer/Brand Shown: Cipla
Common Use: Bladder cancer immunotherapy
Administration: Intravesical instillation only
Category: Prescription medicine
Pack Size: 1 vial, as visible on the pack
Important Label Note: Not intended for immunization

How It Works:

Onco-BCG 40 mg works by stimulating a local immune response inside the bladder. This immune activity may help the body attack or control abnormal bladder cancer cells. BCG used intravesically is an attenuated live strain of Mycobacterium bovis, and it acts as active immunotherapy rather than regular chemotherapy.

Potential Indications:

• Non-muscle invasive bladder cancer
• Carcinoma in situ of the urinary bladder
• Prevention of recurrence of superficial bladder tumors after TURBT
• Other urologist-directed bladder cancer immunotherapy use

Dosage & Storage:

Use only as directed by a qualified urologist or healthcare professional.
This medicine should be prepared and administered only by trained medical staff.
Do not self-administer.
It is given directly into the bladder, not into a vein, muscle, or under the skin. Official BCG immunotherapy guidance states it should not be administered intravenously, subcutaneously, or intramuscularly.
Store strictly as per the physical product label and hospital pharmacy instructions.
Keep out of reach of children.

Important Safety Information:

Onco-BCG should be used only under strict medical supervision. BCG is a live attenuated biological product, so handling, preparation, and disposal require proper precautions. It should generally be avoided or postponed in patients with active urinary tract infection, fever, gross blood in urine, recent bladder surgery/biopsy, traumatic catheterization, active tuberculosis, or significant immune suppression.

Possible side effects may include:

• Burning sensation while urinating
• Frequent urination
• Blood in urine
• Bladder irritation or cystitis-like symptoms
• Fever or chills
• Tiredness or weakness
• Nausea
• Joint pain
• Skin rash
• Urinary tract infection
• Rare serious systemic BCG infection

Serious symptoms such as high fever, chills, persistent cough, breathing difficulty, severe weakness, blood in urine, painful urination that does not improve, or signs of infection should be reported to a doctor immediately. Serious and even fatal disseminated BCG infections have been reported after intravesical BCG use, because apparently even “local therapy” can decide to be dramatic.

Label Verification:

Please double-check the physical product label before listing or use, including product name, strength, active ingredient, manufacturer details, batch number, expiry date, storage instructions, reconstitution instructions, route of administration, and pack contents.

General Information Disclaimer:

The information provided here is for general educational and product-identification purposes only. It should not be considered medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before starting, stopping, or changing any medication regimen.